QuickView for CYP51A1;jsessionid=10E106E3A01D6492F8D4A3BF34871034;jsessionid=DAB8B60ED22C5949EC8EF5210F5C005B;jsessionid=8A58C8BAC67F77C3F97D2E5AC5678AC4;jsessionid=6D4D164F3F073B26521107FC1292082E (gene)

1. Inhibitory effect of magnetic iron-oxide nanoparticles on the pattern of expression of lanosterol 14…
2. Strategies of targeting CYP51 for IFIs therapy: Emerging prospects, opportunities and challenges.
3. Characterization of Prototheca CYP51/ERG11 as a possible target for therapeutic drugs.
4. Male germ cell-specific knockout of cholesterogenic cytochrome P450 lanosterol 14α-demethylase (Cyp5…
5. Synthesis of obtusifoliol and analogues as CYP51 substrates.

There were no clinical trials for CYP51A1;jsessionid=10E106E3A01D6492F8D4A3BF34871034;jsessionid=DAB8B60ED22C5949EC8EF5210F5C005B;jsessionid=8A58C8BAC67F77C3F97D2E5AC5678AC4;jsessionid=6D4D164F3F073B26521107FC1292082E